Načítá se...
Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate
About 20% of patients with a history of atherosclerotic cardiovascular disease will experience further cardiovascular events despite maximal pharmacological treatment with cardioprotective drugs. This highlights the presence of residual cardiovascular risk in a significant proportion of patients and...
Uloženo v:
| Vydáno v: | Drugs Context |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioExcel Publishing Ltd
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6239018/ https://ncbi.nlm.nih.gov/pubmed/30459819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212557 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|